ArticleScientific reports2021
The outcomes of acute myocardial infarction patients comorbidity with hypertension and hyperhomocysteinemia.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Epidemiological Trends in Mortality From Acute Myocardial Infarction With Essential and Secondary Hypertension: CDC WONDER Database Analysis, 2000-2024.Clinical cardiology · 2026Review
- Evaluation of Serum Homocysteine and High-Sensitivity Cardiac Troponins in Cats with Hepatic Lipidosis: An Observational Clinical Study.Veterinary sciences · 2026Article
- Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments.Molecular and cellular biochemistry · 2025Review
- Prognosis modelling of adverse events for post-PCI treated AMI patients based on inflammation and nutrition indexes.BMC cardiovascular disorders · 2025Article
- Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.Clinical interventions in aging · 2025Article
- Effect of Recombinant Human Brain Natriuretic Peptide Therapy After PCI in Patients with Acute Myocardial Infarction and Its Impact on Cardiac Function: A Retrospective Controlled Study.International journal of general medicine · 2025Article
- Clinical Predictors of the Rapid Progression and Revascularization of Coronary Non-Target Lesions: A Serial Angiographic Study.Reviews in cardiovascular medicine · 2024Article
- Prevalence and clinical correlates of hyperhomocysteinemia in Chinese urban population with hypertension.Frontiers in endocrinology · 2024Article
- Article
- Outcome effects of enalapril with or without bisoprolol in patients with acute myocardial infarction.American journal of translational research · 2023Article
- Article
- Recurrent acute coronary syndrome after infliximab infusion in a patient with rheumatoid arthritis: Case report.Colombia medica (Cali, Colombia)Article
- Risk factors and prediction nomogram model for 1-year readmission for major adverse cardiovascular events in patients with STEMI after PCI.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the outcomes and major adverse cardiovascular events (MACEs) incurred by acute myocardial infarction (AMI) patients comorbiding with hypertension and hyperhomocysteinemia (HHcy) during hospitalization and 1-year follow-up. 648 consecutive AMI patients were divided into four categories: (1) hypertension with Hcy ≥ 15 µmol/L; (2) hypertension with Hcy < 15 µmol/L; (3) no-hypertension with Hcy ≥ 15 µmol/L; (4) no-hypertension with Hcy < 15 µmol/L. Information taken from these case files included gender, past medical history, vital signs, laboratory examination, electrocardiogram, coronary angiography, cardiac ultrasound, and medicine treatment. The primary endpoints were duration of coronary care units (CCU) stay, duration of in-hospital stay, and MACEs during follow-up. Our data show that hypertension and HHcy have a synergistic effect in AMI patients, AMI comorbiding with hypertension and HHcy patients had more severe multi-coronary artery disease and more frequent non-culprit coronary lesions complete clogging, had a higher prevalence of pro-brain natriuretic peptide, and significant decreases in the left ventricular ejection fraction. These patients had significant increases in the duration of CCU stay and in-hospital stay, had significant increase in the rate of MACEs, had significant decreases in the survival rate during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.